Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Ribosomal RNA (rRNA) is the catalytic and structural component of the ribosome, the cellular machinery responsible for protein synthesis. In bacteria, the ribosome consists of the 30S and 50S subunits, containing the 16S, 23S, and 5S rRNA molecules, which serve as the primary targets for a wide range of clinically important antibiotics. These drugs bind to specific functional sites, such as the decoding center on the 16S rRNA or the peptidyl transferase center (PTC) on the 23S rRNA, to inhibit translation. Beyond these well-characterized pockets, 'additional ribosomal rRNA sites' refer to emerging or non-canonical binding regions being explored to overcome antibiotic resistance or to target eukaryotic rRNA in diseases like cancer. Because rRNA is highly conserved yet possesses distinct structural differences between prokaryotes and eukaryotes, it remains a cornerstone for selective toxicity in antimicrobial therapy.
Inhibition of protein synthesis by binding to specific sites on the ribosomal RNA, leading to interference with decoding, translocation, or peptidyl transfer.
9 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ribosomal ribonucleic acid (rRNA) (rRNA).